- Key facts & figures
- Sanofi share
- Analysts / Vara Consensus
- Reports & publications
- Results & presentations
- Corporate governance
Annual General Meetings
- Our publications
- Being a shareholder
- Becoming a shareholder
- Shareholders committee
- U.S. investors
- Regulated information in France
- Get to know Sanofi
- Working at Sanofi
- Our Expertise, your future
- Join Sanofi
- Being our partner
- Understanding science discovering
- Developing and marketing innovative solutions
- Manufacturing and supply
- Healthcare Solutions
- Our approach
- Improving access to healthcare
- Working together
- Ethics and transparency
- Preserving the environment
- ‘LE HUB’ eMAG
One of the major challenges MS poses is the simple fact that it is not well understood. It is thought to be the result of a genetic predisposition combined with an environmental or viral factor.
Understanding Multiple Sclerosis
As there are no specific tests for MS, diagnosis can only be made after evaluating damage to the central nervous system and ruling out other possibilities.
Living with Multiple Sclerosis
Dean, who lives in Queensland, Australia, is 45 and married with two daughters. In 2007, he found out he had multiple sclerosis. Today, thanks to his treatment, he has regained control over his body and can continue enjoying life to the fullest.
Watch his story:
How we work to tackle Multiple Sclerosis
Sanofi Genzyme has worked for over a decade to develop new treatments for MS, establishing itself as a leader in providing therapies for the disorder, with two marketed products and several products under development.
While many existing treatments modulate the disease’s symptoms, we are focusing on developing therapies that have the potential to modulate the damaged immune system. We also focus our research on agents that can protect and promote repair of the myelin sheath.
At Sanofi Genzyme, our extensive experience in ultra-rare diseases has shown us that fostering truly personalized medicine is also crucial to effectively treating disorders like MS. We do this by developing relationships with patients and caregivers, healthcare providers and disease organizations and foundations.
We have no doubt that the only way forward is to understand the experiences, challenges and even triumphs of those affected by MS.
“We’re inspired every day by people living MS and the people who care for them, and we’re constantly pushing ourselves to transform what it means to receive an MS diagnosis,” said Bill Sibold, Sanofi Genzyme Franchise Head, Multiple Sclerosis, Oncology and Immunology.
Engaging with civil society
“The patients are our prime source of mobilization and inspiration.” Dr. Christian Deleuze, Sanofi Genzyme, France.
We are a proud partner of important patient organizations working on crucial, large-scale initiatives focused on meeting critical unmet needs in the MS community. Learn more about the programs we support on our website.
In addition to this, Sanofi Genzyme has developed “vs.MS”, a global initiative aimed at uncovering the often unspoken challenges of MS. More specifically, it fielded a global survey among more than 1 500 people living with relapsing MS (RMS) and their care partners across seven countries to encourage behaviour and attitude shifts and drive better, more informed care.
Sanofi Genzyme also developed a seven-week online program, “Spirit: Live a Better Life with MS”, for people living with MS in Norway, Denmark, Sweden and Finland. The program is based on the newest research in health and positive psychology and focuses on inner personal strength. (See www.sanofigenzyme.com / Patient Support Services for more information.)
For the availability of our healthcare solutions in your country, please consult your local Sanofi website.
Sanofi Genzyme is an innovator in the treatment of multiple sclerosis.
- N. Danziger. Neurologie. Med-Line Editions, 2011, p.107